XML 41 R23.htm IDEA: XBRL DOCUMENT v3.25.2
SEGMENT REPORTING
 12 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
SEGMENT REPORTING

NOTE 14 — SEGMENT REPORTING

 

For the year ended June 30, 2025, the Company had three reportable segments. These segments have different strategic and economic goals and are managed separately because they require different technology and marketing strategies.

 

Reportable Segment   Description
RENB   Developing new immunotherapies to combat cancer
BioSymetrics   Integrating multimodal data sources, including genomics, imaging, electronic health records, and other real-world evidence, to advance biomarker discovery, therapeutic development, and precision medicine.
RENC   Developing a predicative artificial intelligence based diagnostic methodology for the use of earlier cancer detection

 

The Company’s chief executive officer is the chief operating decision maker and reviews the internal management reports for each segment at least quarterly. During the year ended June 30, 2025, there were no significant inter-company revenues or expenses. The chief operating decision maker assesses performance for each segment and decides how to allocate resources based on segment operating losses that also is reported on the consolidated statement of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets. The accounting policies of each segment are the same as those described in the summary of significant accounting policies.

 

          
   Operating loss  Assets
United States (RENB)  $15,530,056   $1,907,647 
United States (BioSymetrics)   237,880    6,109,643 
Netherlands (RENC)   173,198,066    213,550 
   $188,966,002   $8,230,840 

 

The chief operating decision maker uses loss from operations to evaluate the performance of each segment’s assets in deciding how to allocate available capital between segments. The chief operating decision maker also uses loss from operations in their competitive analysis by benchmarking the Company’s competitors. The competitive analysis along with the monitoring of budgeted versus actual results are used in assessing the performance of the segment.

 

Information regarding each reportable segment for the year ended June 30, 2025 is as follows:

 

                    
   RENB  BioSymetrics  RENC  Total
General and administrative  $14,904,855   $211,401   $2,763,794   $17,880,050 
Research and development   502,896    26,029    8,503    537,428 
Goodwill impairment   —    —    170,419,429    170,419,429 
Depreciation and amortization   122,305    450    6,340    129,095 
                     
Segment operating loss  $15,530,056   $237,880   $173,198,066    188,966,002 

 

Geographic information:

 

RENB, BioSymetrics and RENC are managed on a worldwide basis but operate in offices located in the United States and the Netherlands, respectively. The geographic information analyses the Company’s operations and assets based on the country in which each segment operates. In presenting this geographic information, segment operating results have been based on the geographic location in which the services were provided to the segment and segment assets were based on the geographic location of the assets.